重新編碼的健康風險

2023年4月11日

信使rna平台公司合理的生物技術已宣布了一項420萬美元計劃輪加速細胞的發展平台的製造高質量的信使rna。和公司的技術旨在克服當前信使rna製造工藝的限製,確保可伸縮的和具有成本效益的生產高質量的信使rna。計劃資金輪由BlueYard資本,在Y Combinator的參與下,氨基集體、文明企業,重新編碼健康企業,ZAKA。Florian舒斯特爾,傑森·c·福斯特,和其他生命科學高管和天使投資。COVID-19大流行證明了信使rna技術的巨大潛力將小說mRNA-based療法。但目前,信使rna製造方法稱為遊離體外轉錄(溶)不能提供mRNA有足夠的質量,它的許多核心臨床應用。和信使rna通過診斷需要使用昂貴的和專有的酶和不擴展到大量的反應。加上合理的生物技術的細胞平台將致力於提供一個可擴展的和可負擔得起的高質量的生產信使rna信使rna技術的潛力擴大到小說形式。計劃的資金流動中遵循合理的公告與銀杏生物工作室,一個戰略夥伴關係本周早些時候宣布。和明智的將利用銀杏的能力加快明智的mRNA的發展平台。 KEY QUOTES: “This funding will enable us to advance the development of our cell-based mRNA manufacturing platform and to unlock the full potential of mRNA technology in life-saving therapies, while strengthening the robustness of the mRNA supply chain. We are thrilled to be backed by BlueYard Capital and its co-investors and build Sensible Biotechnologies with their support.” — Miroslav Gasparek, the CEO and Co-Founder of Sensible Biotechnologies “Sensible Biotechnologies is on a mission to unlock the full potential of mRNA and its clinical applications. We are excited to support Sensible’s work at the intersection of biology and technology, which has the potential to disrupt the status quo in mRNA manufacturing and create a vertically integrated mRNA platform.” — Jason Whitmire, Co-Founder and General Partner at BlueYard Capital Trending on Pulse 2.0